Spravato Nasal Esketamine Treatment
The first FDA-approved ketamine-based treatment
Esketamine, also known as Spravato, is a low-dose, ketamine-based treatment for depression that’s covered by most insurance. In 2019, Spravato became the first FDA-approved prescription nasal spray to treat:
- Adults with treatment-resistant depression
- Depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions
Spravato works differently to relieve depressive symptoms. While traditional oral antidepressants increase levels of neurotransmitters in areas of the brain that affect mood, Spravato targets the N-methyl-D-aspartate (NMDA) receptor and has the ability to work rapidly.
During treatment, patients administer Spravato esketamine nasal spray themselves under the supervision of a healthcare provider. After administration, there’s an observation period during which patients can listen to music, or rest comfortably in our private treatment centers. By the next morning, most people are ready to resume their day with no restrictions.
Who is a candidate
Is Spravato right for you?
If you’ve tried two or more oral medications and are still struggling with depressive symptoms, you might consider Spravato esketamine nasal spray. Spravato may be your next step if you:
Your Behavioral Health represents a REMS-certified, in-network provider of Spravato delivering treatment that’s up to 100% covered by insurance.